Jubilant Pharmova Ltd.

₹1,022.6

1.9 (0.2%)

JUBLPHARMA Share Price

Pharmaceuticals & Biotechnology

As on July 17, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 16,145 Cr

P/E Ratio19.25

Dividend Yield0.49 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,003.77	Bullish
10-DMA	988.35	Bullish
20-DMA	977.98	Bullish
50-DMA	983.95	Bullish
100-DMA	929.73	Bullish
200-DMA	994.97	Bullish

Historical Performance

1 Year

-14.8%

3 Years

163.6%

5 Years

43.3%

10 Years

239.1%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	72,345	67,029	62,817	61,302	60,985
Total Expenditure	60,608	58,021	55,055	49,738	47,021
Other Income	568	687	383	113	176
Operating Profit	12,305	9,695	8,145	11,676	14,141
Interest	2,403	2,723	1,882	1,455	1,841
Depreciation	3,686	3,819	5,540	3,817	3,489
Profit Before Tax	9,806	1,705	278	6,304	8,711
Consolidated Net Profit	8,394	771	-610	4,139	8,359
Adjusted EPS	53	5	-4	26	53

Compounded Sales Growth

10 Years:4.4

5 Years:3.9

3 Years:3.4

TTM:1.5

Compounded Profit Growth

10 Years:38.2

5 Years:-1.3

3 Years:15.2

TTM:61.2

Stock Price CAGR

10 Years:13

5 Years:7.3

3 Years:38.3

TTM:-17

Return on Equity

10 Years:25.2

5 Years:52.5

3 Years:-3.8

last year:53.1

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	158	158	159	159	159
Total Reserves	62,243	54,036	53,772	52,990	47,248
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	40,958	40,057	37,650	29,216	29,730
Other Current Liabilities	8,440	7,328	5,521	8,385	3,717
Short Term Borrowings	2,190	1,965	2,583	640	200
Total Liabilities	1,24,990	1,13,158	1,09,292	98,296	87,634
Capital Work in Progress	27,147	12,523	7,733	2,918	2,778
Long Term Loans & Advances	541	1,919	1,615	1,176	628
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	2,463	2,280	2,713	2,312	2,051
Total Current Assets	35,097	36,322	37,624	35,092	29,525
Total Assets	1,24,990	1,13,158	1,09,292	98,296	87,634
Adjusted Book Value	395	343	339	334	298

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 19.25, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a strong 3-year price CAGR of 38.3%, indicating sustained price appreciation.
The stock carries a low beta of 0.7, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹12305 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹72345 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 836551

No. of Shares: 818 (Approx)

Performance:-16.3%

-163449

NIFTY Performance: -2.5%

1 day Top Gainers